tbuckley/cabot-search huggingface dataset:
Extended-spectrum β-lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study
Authors: Michaela J Day, Katie L Hopkins, David W Wareham, Mark A Toleman, Nicola Elviss, Luke Randall, Christopher Teale, Paul Cleary, Camilla Wiuff, Michel Doumith, Matthew J Ellington, Neil Woodford, David M Livermore
Journal: The Lancet Infectious Diseases (2019)

BackgroundExtended-spectrum β-lactamase-producing Escherichia coli isolates (ESBL-E coli) cause more than 5000 cases of bacteraemias annually in the UK. The contribution of the food chain to these infections is debated. We aimed to identify the most important reservoirs of ESBL-E coli that colonise and infect humans to identify strategic intervention points.MethodsSampling for ESBL-E coli was done between Aug 1, 2013, and Dec 15, 2014. We used selective media to seek ESBL-E coli in routinely submitted samples from human faeces, and prospectively collected samples from sewage, farm slurry, and retail foodstuffs in London, East Anglia, northwest England, Scotland, and Wales. We sequenced recovered isolates and compared these isolates with 293 bloodstream and 83 veterinary surveillance ESBL-E coli isolates from the same regions.Findings2157 (11%) of 20 243 human faeces samples contained ESBL-E coli, including 678 (17%) of 3995 in London. ESBL-E coli also were frequent in sewage and retail chicken (104 [65%] of 159 meat samples), but were rare in other meats and absent from plant-based foods (0 of 400 fruit and vegetable samples). Sequence type (ST) 131 dominated among ESBL-E coli from human blood (188 [64%] of 293 isolates), faeces (128 [36%] of 360), and sewage (14 [22%] of 65) with STs 38 and 648 also widespread; CTX-M-15 was the predominant ESBL in these lineages (319 [77%] of 416). By contrast, STs 602, 23, and 117—mostly with CTX-M-1 ESBL—dominated among food and veterinary isolates (68 [31%] of 218), with only two ST131 organisms recovered. ST10 occurred in both animals and humans, being frequent in surveillance bovines (11 [22%] of 51 cattle) and representing 15 (4%) of 360 human faecal isolates (but only three [1%] of 293 from bacteraemias); however, both human and animal ST10 isolates were diverse in serotype.InterpretationMost human bacteraemias with ESBL-E coli in the UK involve internationally prevalent human-associated STs, particularly ST131; non-human reservoirs made little contribution to invasive human disease. Any interventions that seek to target food or livestock can affect the numbers of human infections caused by ESBL-E coli; prevention of the spread of resistant lineages among humans is more vital.FundingNIHR Policy Research.
P1.01-07 Real World Data of Docetaxel Plus Nintedanib for Pretreated NSCLC Patients: 4 Yrs Update Compassionate Use Program Single Institution in Mexico
Authors: S. Campos-Gomez, K. Campos-Gomez, J.J. Valdéz-Andrade, J. Esquivel Gutierrez
Journal: Journal of Thoracic Oncology (2019)
P1.03-02 Nintedanib Selectively Inhibits Angiogenesis Induced by the Conditioned Medium of Lung Adenocarcinoma TAFs in Vitro
Authors: N. Díaz-Valdivia, P. Duch, R. Ikemori, M. Gabasa, F. Hilberg, N. Reguart, J. Alcaraz
Journal: Journal of Thoracic Oncology (2019)
P1.16-14 Effects of an Artificial Intelligence (AI) System on Clinical Trial Enrollment in Lung Cancer
Authors: K. Leventakos, J. Helgeson, A. Mansfield, E. Deering, A. Schwecke, A. Adjei, J. Molina, C. Hocum, K. Parikh, T. Halfdanarson, R. Marks, T. Bleeker, K. Pomerleau, S. Coverdill, M. Rammage, A. Preininger, G. Purcell Jackson, T. Haddad
Journal: Journal of Thoracic Oncology (2019)
No more butts
Authors: May C I van Schalkwyk, Thomas E Novotny, Martin McKee
Journal: BMJ (2019)

Reducing plastic pollution means banning the sale of filtered cigarettes Growing awareness of the harm done to ecosystems through disposal of vast quantities of plastic has created public outrage and compelled governments to act.1 The European Union, for example, will ban many single-use plastic products, such as cutlery, plates, and straws, from 2021.2 However, these measures do not extend to one of the leading sources of plastic waste worldwide that is hiding in plain sight: the cigarette butt. The largest part of most cigarette butts is a non-biodegradable plastic filter made of cellulose acetate.3 Filters first appeared in the 1950s following early health concerns about cigarettes, and their rapid adoption was helped by the post-war explosion in manufacturing of plastics.4 The tobacco industry portrayed filters as a way to make cigarettes safer by absorbing some of the "tar" that was implicated in the lung cancer epidemic. We now know that this safety argument was a myth (box 1), one of many created by the tobacco industry to sell cigarettes.6 Box 1 ### Filtering the truth • "Filters are the deadliest fraud in the history of human civilization. They are put on cigarettes to save on the cost of tobacco and to fool people. They … RETURN TO TEXT
Unilateral Lateral Rectus Paralysis Showing Incomplete “V” Sign’ on 18F-FDG PET/CT
Authors: Ashwin Singh Parihar, Shelvin Kumar Vadi, Rajender Kumar, Harmandeep Singh, Aastha Takkar, Bhagwant Rai Mittal, Vivek Lal
Journal: Clinical Nuclear Medicine (2019)

Abstract Extraocular muscles show physiologic radiotracer uptake on 18 F-FDG PET/CT as is encountered in most routine scans. Certain pathologies can cause palsy of one or more of the extraocular muscles, leading to hypometabolism on 18 F-FDG PET/CT. We present a case with a classical finding of unilateral hypometabolism of the lateral rectus muscle, disrupting the “V” sign formed due to physiologic uptake. The patient had presented with the complaint of diplopia and was being evaluated further to rule out the possibility of inflammatory/granulomatous infectious etiopathogenesis leading to compression of the abducens nerve resulting in lateral rectus palsy.
Alterations in Bone Homeostasis and Microstructure Related to Depression and Allostatic Load
Authors: Pia-Maria Wippert, Andrea Block, Isabelle M. Mansuy, Eva M.J. Peters, Matthias Rose, Michael A. Rapp, Alexander Huppertz, Karin Wuertz-Kozak
Journal: Psychotherapy and Psychosomatics (2019)
MA23.07 Loss of Expression of BAP1 and/or MTAP Aids in the Diagnosis of Malignant Mesothelioma Metastatic to Lymph Nodes
Authors: A.C. Roden, T. Peikert, J. Vrana, A. Hudson, D. Wigle, M.C. Aubry, A. Mansfield
Journal: Journal of Thoracic Oncology (2019)
P2.17-41 Treatment Outcomes of Pulmonary Resection in NSCLC Patients with Autoimmune Diseases
Authors: S. Fukuda, K. Suda, S. Ohara, M. Nishino, M. Chiba, T. Takemoto, J. Soh, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2019)
EP1.01-73 Trousseau’s Syndrome Associated with Pulmonary Pleomorphic Carcinoma Showing Aggressive Features: A Case Report
Authors: S. Okada, A. Miyagawa-Hayashino, J. Fujinami, K. Kameyama, S. Kitaoka, N. Ishikawa, T. Furuya, S. Ikebe, S. Ishihara, H. Tsunezuka, M. Shimomura, J. Shimada, M. Inoue
Journal: Journal of Thoracic Oncology (2019)
EP1.12-20 Retrospective Study About the Impact of Metastatic Site in Small Cell Lung Cancer
Authors: D. Sanchez Cabrero, P. Cruz, P. Perez, S. Martinez, O. Higuera, A. Pertejo, I. Esteban, L. Gutierrez, J. Villamayor, D. Viñal, J.L. Torres, J. Ramón, J. De Castro Carpeno
Journal: Journal of Thoracic Oncology (2019)
OA15.04 Genomic and TCR Intratumor Heterogeneity of Small-Cell Lung Cancer by Multiregion Sequencing: An Association with Survival
Authors: R. Chen, Y. Jin, J. Li, J. Zhang, J. Fujimoto, W. Lee, X. Hu, Y. Chen, C. Behrens, C. Chow, E. Parra, L. Little, C. Gumbs, X. Song, E. Roarty, J. Zhang, D. Gibbons, J. Heymach, J.J. Lee, W. William, B. Glisson, I. Wistuba, P.A. Futreal, L. Byers, A. Reuben, M. Chen, J. Zhang
Journal: Journal of Thoracic Oncology (2019)
P2.04-03 Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting
Authors: J. Assié, F. Cotté, M. Giaj Levra, C. Calvet, R. Jolivel, B. Jouaneton, A. Gaudin, V. Grumberg, C. Chouaid, R. Corre
Journal: Journal of Thoracic Oncology (2019)
P1.11-09 Risk of Second Primary Malignancy After Non-Small-Cell Lung Cancer: A Competing Risk Nomogram Based on the SEER Database
Authors: H. Zhou, J. Shen, Y. Zhang, Y. Huang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, X. Chen, Z. Zhang, J. Liu, W. Xian, Y. Zhao, X. Hou, Y. Ma, T. Zhou, H. Zhao, L. Zhang
Journal: Journal of Thoracic Oncology (2019)
P2.06-08 Nivolumab for Malignant Mesothelioma: A Real-World Experience
Authors: M. Niki, T. Yokoi, R. Takahashi, K. Mikami, E. Shibata, Y. Nakajima, Y. Negi, H. Ishigaki, A. Tada, T. Higashiyama, T. Kamei, T. Minami, K. Kuribayashi, T. Kijima
Journal: Journal of Thoracic Oncology (2019)
MA13.11 A Randomized Phase III Study of Cisplatin-Polymeric Micelle Paclitaxel vs Cisplatin-Solvent-Based Paclitaxel in 1st Line Advanced NSCLC
Authors: Y. Wu, B. Han, M. Shi, H. Tu, A. Gu, C. Huang, H. Wang, Z. Yu, X. Wang, L. Cao, Y. Shu, H. Wang, R. Yang, X. Li, J. Chang, Y. Hu, P. Shen, Y. Hu, Z. Guo, M. Tao, Y. Zhang, X. Liu, Q. Sun, X. Zhang, Z. Jiang, J. Zhao, F. Chen, J. Sun, D. Li, J. Zhou
Journal: Journal of Thoracic Oncology (2019)
MA02.07 A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients with Early Stage Non-Small Cell Lung Cancer
Authors: M. Daly, A. Monjazeb, A. Mirhadi, D. Eastham, F. Lara, J. Riess, E. Wiegner, K. Kelly
Journal: Journal of Thoracic Oncology (2019)
OA10.07 Concordance Between ROSE and Final Diagnosis in Patients Undergoing EBUS- TBNA for Non-Small Cell Lung Cancer Staging
Authors: C. Caupena Auledas, M. Martinez Palau, B. García Cabo, T. Pribic, L. Esteban Tejero, F. Perez Ochoa, R. Albero Gonzalez, C. Ferrer Cassado, P. Forcada Guiu, S.P. Pontes De Sousa, X. Tarroch Sarasa, J. Sanz Santos
Journal: Journal of Thoracic Oncology (2019)
Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552]
Authors: Thomas Yau, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Yoon-Koo Kang, Ming-Mo Hou, Kazushi Numata, Winnie Yeo, Akhil Chopra, Masafumi Ikeda, Ryoko Kuromatsu, Michihisa Moriguchi, Yee Chao, Huanyu Zhao, Jeffrey Anderson, Christine Dela Cruz, Masatoshi Kudo
Journal: Journal of Hepatology (2019)
P2.11-15 Detection of Circulating Genetically Abnormal Cells Improves the Diagnostic Accuracy in Lung Cancer Presenting with GGNs
Authors: B. Zhang, S. He, C. Chen, Y. Chen, Y. Li, M. Huang, D. Yue, C. Huang, C. Li, Y. Xin, J. Zhang, C. Wang
Journal: Journal of Thoracic Oncology (2019)
P2.09-15 PD-L1 Expression and Lymphocyte Infiltration in Resected Stage IIIAN2 NSCLC: Preliminary Data from a Lung ART Ancillary Study
Authors: J. Adam, A. Bardet, V. Thomas De Montpreville, F. Barlesi, N. Pourel, G. Noël, U. Nestle, O. Mercier, J. Edwards, P.A. Thomas, C. Le Pechoux
Journal: Journal of Thoracic Oncology (2019)
P2.04-42 PD-L1-Mediated Enhancement of Hexokinase 2 Expression Is Inversely Related to T-Cell Effector Gene Expression in Non-Small-Cell Lung Cancer
Authors: S. Kim, J. Jang, J. Koh, D. Kwon, Y.A. Kim, J.C. Paeng, C. Ock, B. Keam, M. Kim, T.M. Kim, D.S. Heo, D.H. Chung, Y.K. Jeon
Journal: Journal of Thoracic Oncology (2019)
A young woman with dyspnoea and oedema
Authors: Catherine Spilsbury, Mona Panahi, Gemma Bowsher, Ashkan Sadighi
Journal: BMJ (2019)

A 25 year old woman was admitted with a five day history of worsening shortness of breath and peripheral oedema. She had a history of suboptimal glycaemic control for type 1 diabetes that was diagnosed 10 years ago. She had had chronic kidney disease (CKD) for the past two years, with a gradually declining estimated glomerular filtration rate (eGFR) and rising creatinine level (previously asymptomatic).

Examination revealed muscle spasm in both hands, bilateral pitting thigh oedema, abdominal distention, and facial swelling. Auscultation revealed reduced air entry bilaterally and fine bibasal crepitations. Chest radiograph showed subsegmental …
Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality
Authors: Chetasi Talati, Andrew Kuykendall, Najla Al Ali, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, David A Sallman, Alan F List, Eric Padron, Rami S. Komrokji, Benjamin Djulbegovic, Martine Extermann, Kendra Sweet, Jeffrey E. Lancet
Journal: Blood (2017)
P2.04-91 Target Antigen Levels in NSCLC Define a Clinically Relevant Activation Threshold for NY-ESO-1c259 TCR T-Cell Therapy
Authors: I. Eleftheriadou, S. Brett, A. Domogala, L. Patasic, M. Kijewska, K. Soor, J. Jing, J. Euesden, K. Auger, R. Roberts, S. O’sullivan, L. Castelletti, M. Damm, J. Klapwijk, J. Spaull, D. Pankov, L. Johnsons, A. Shalabi, C. Britten
Journal: Journal of Thoracic Oncology (2019)
Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase
Authors: Max Drabkin, Yuval Yogev, Lior Zeller, Raz Zarivach, Ran Zalk, Daniel Halperin, Ohad Wormser, Evgenia Gurevich, Daniel Landau, Rotem Kadir, Yonatan Perez, Ohad S Birk
Journal: Journal of Clinical Investigation (2019)

Gout is caused by deposition of monosodium urate crystals in joints when plasma uric acid levels are chronically elevated beyond the saturation threshold, mostly due to renal underexcretion of uric acid. Although molecular pathways of this underexcretion have been elucidated, its etiology remains mostly unknown. We demonstrate that gout can be caused by a mutation in LDHD within the putative catalytic site of the encoded d-lactate dehydrogenase, resulting in augmented blood levels of d-lactate, a stereoisomer of l-lactate, which is normally present in human blood in miniscule amounts. Consequent excessive renal secretion of d-lactate in exchange for uric acid reabsorption culminated in hyperuricemia and gout. We showed that LDHD expression is enriched in tissues with a high metabolic rate and abundant mitochondria and that d-lactate dehydrogenase resides in the mitochondria of cells overexpressing the human LDHD gene. Notably, the p.R370W mutation had no effect on protein localization. In line with the human phenotype, injection of d-lactate into naive mice resulted in hyperuricemia. Thus, hyperuricemia and gout can result from the accumulation of metabolites whose renal excretion is coupled to uric acid reabsorption.
Association of the Functional Medicine Model of Care With Patient-Reported Health-Related Quality-of-Life Outcomes
Authors: Michelle Beidelschies, Marilyn Alejandro-Rodriguez, Xinge Ji, Brittany Lapin, Patrick Hanaway, Michael B. Rothberg
Journal: JAMA Network Open (2019)

<h3>Importance</h3> The incidence of chronic disease is increasing along with health care–related costs. The functional medicine model of care provides a unique operating system to reverse illness, promote health, and optimize function. The association between this model of care and patient's health-related quality of life (HRQoL) is unknown. <h3>Objective</h3> To assess the association between functional medicine and patient-reported HRQoL using Patient-Reported Outcome Measurement Information System (PROMIS) global health measures. <h3>Design, Setting, and Participants</h3> A retrospective cohort study was performed to compare 7252 patients aged 18 years or older treated in a functional medicine setting with propensity score (PS)–matched patients in a primary care setting. Sensitivity analyses assessed improvement limited to patients seen at both 6 and 12 months. The study included patients who visited the Cleveland Clinic Center for Functional Medicine or a Cleveland Clinic family health center between April 1, 2015, and March 1, 2017. <h3>Main Outcomes and Measures</h3> The primary outcome was change in PROMIS Global Physical Health (GPH) at 6 months. Secondary outcomes included PROMIS Global Mental Health (GMH) at 6 months and PROMIS GPH and GMH at 12 months. The PROMIS GPH and GMH scores were transformed to a<i>T</i>-score from 0 to 100 with a mean of 50. Higher scores indicate a better health-related quality of life. <h3>Results</h3> Of the 7252 patients (functional medicine center: 1595; family health center: 5657), 4780 (65.9%) were women; mean (SD) age was 54.1 (16.0) years. At 6 months, functional medicine patients exhibited significantly larger improvements in PROMIS GPH<i>T</i>-score points than were seen in patients treated at a family health center (mean [SD] change, functional medicine center: 1.59 [6.29] vs family health center: 0.33 [6.09],<i>P</i> = .004 in 398 PS-matched pairs). At 12 months, functional medicine patients showed improvement similar to that observed at 6 months; however, comparisons with patients seen at the family health center were not significant. Patients in the functional medicine center with data at both 6 and 12 months demonstrated improvements in PROMIS GPH (mean [SD], 2.61 [6.53]) that were significantly larger compared with patients seen at a family health center (mean [SD], 0.25 [6.54]) (<i>P</i> = .02 in 91 PS-matched pairs). <h3>Conclusions and Relevance</h3> In this study, the functional medicine model of care demonstrated beneficial and sustainable associations with patient-reported HRQoL. Prospective studies are warranted to confirm these findings.
EP1.15-08 Association of Perioperative Chemotherapy with Survival in Thymic Malignancies
Authors: K. Parikh, U. Durani, S. Funni, J. Inselman, G. Goyal, K. Leventakos, N. Duma, S. Yadav, R. Go, A. Mansfield
Journal: Journal of Thoracic Oncology (2019)
P1.16-34 Association Between Skin Reactions and Clinical Benefit in Patients Treated with Anti-PD-1 Treatment for Advanced Non-Small Cell Lung Cancer
Authors: M. Aso, S. Sugawara, Y. Toi, J. Sugisaka, H. Ono, T. Aiba, S. Kawana, R. Saito, K. Tsurumi, K. Ono, H. Shimizu, Y. Domeki, K. Terayama, Y. Kawashima, A. Nakamura, S. Yamanda, Y. Kimura, Y. Honda
Journal: Journal of Thoracic Oncology (2019)
Computational Framework for High-Quality Production and Large-Scale Evolutionary Analysis of Metagenome Assembled Genomes
Authors: Boštjan Murovec, Leon Deutsch, Blaz Stres
Journal: Molecular Biology and Evolution (2019)

Abstract Microbial species play important roles in different environments and the production of high-quality genomes from metagenome data sets represents a major obstacle to understanding their ecological and evolutionary dynamics. Metagenome-Assembled Genomes Orchestra (MAGO) is a computational framework that integrates and simplifies metagenome assembly, binning, bin improvement, bin quality (completeness and contamination), bin annotation, and evolutionary placement of bins via detailed maximum-likelihood phylogeny based on multiple marker genes using different amino acid substitution models, next to average nucleotide identity analysis of genomes for delineation of species boundaries and operational taxonomic units. MAGO offers streamlined execution of the entire metagenomics pipeline, error checking, computational resource distribution and compatibility of data formats, governed by user-tailored pipeline processing. MAGO is an open-source-software package released in three different ways, as a singularity image and a Docker container for HPC purposes as well as for running MAGO on a commodity hardware, and a virtual machine for gaining a full access to MAGO underlying structure and source code. MAGO is open to suggestions for extensions and is amenable for use in both research and teaching of genomics and molecular evolution of genomes assembled from small single-cell projects or large-scale and complex environmental metagenomes.
Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop
Authors: Timothy P. Hughes, Andreas Hochhaus, Dong-Wook Kim, Francois-Xavier Mahon, Francis J. Giles, Jerald P. Radich, David M Ross, Prashanth Gopalakrishna, Weiping Deng, Rafik Fellague-Chebra, Sandip Acharya, Giuseppe Saglio
Journal: Blood (2017)
P2Y6 signaling in alveolar macrophages prevents leukotriene-dependent type 2 allergic lung inflammation
Authors: Jun Nagai, Barbara Balestrieri, Laura B. Fanning, Timothy Kyin, Haley Cirka, Junrui Lin, Marco Idzko, Andreas Zech, Edy Y. Kim, Patrick J. Brennan, Joshua A. Boyce
Journal: Journal of Clinical Investigation (2019)

Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT1R) are widely used to treat asthma and allergic rhinitis, with variable response rates. Alveolar macrophages express UDP-specific P2Y6 receptors that can be blocked by off-target effects of CysLT1R antagonists. Sensitizing intranasal doses of an extract from the house dust mite Dermatophagoides farinae (Df) sharply increased the levels of UDP detected in bronchoalveolar lavage fluid of mice. Conditional deletion of P2Y6 receptors before sensitization exacerbated eosinophilic lung inflammation and type 2 cytokine production in response to subsequent Df challenge. P2Y6 receptor signaling was necessary for dectin-2–dependent production of protective IL-12p40 and Th1 chemokines by alveolar macrophages, leading to activation of NK cells to generate IFN-γ. Administration of CysLT1R antagonists during sensitization blocked UDP-elicited potentiation of IL-12p40 production by macrophages in vitro, suppressed the Df-induced production of IL-12p40 and IFN-γ in vivo, and suppressed type 2 inflammation only in P2Y6-deficient mice. Thus, P2Y6 receptor signaling drives an innate macrophage/IL-12/NK cell/IFN-γ axis that prevents inappropriate allergic type 2 immune responses on respiratory allergen exposure and counteracts the Th2 priming effect of CysLT1R signaling at sensitization. Targeting P2Y6 signaling might prove to be a potential additional treatment strategy for allergy.
Correction: Preeclampsia and risk of end stage kidney disease: A Swedish nationwide cohort study
Authors: Ali S. Khashan, Marie Evans, Marius Kublickas, Fergus P. McCarthy, Louise C. Kenny, Peter Stenvinkel, Tony Fitzgerald, Karolina Kublickiene
Journal: PLoS Medicine (2019)

[This corrects the article DOI: 10.1371/journal.pmed.1002875.].
Pulmonary Hypertension in Adults and Children with Sickle Cell Disease in Nigeria: Prevalence, Clinical Characteristics and Role of Endemic Tropical Infections.
Authors: Zakari Y. Aliyu, Sachdev Vandana, Aisha I. Mamman, Aliyu Babadoko, Peter Akpanpe, Ester Attah, Yusuf Suleiman, Nurudeen Aliyu, Jamilu Yusuf, Laurel Mendelsohn, Wynona Coles, Solomon Danbauchi, James Taylor, Oswaldo Castro, Victor R. Gordeuk, William C. Blackwelder, Gregory J. Kato, Mark T. Gladwin
Journal: Blood (2007)